{"id":"W3195243079","doi":"10.1182/blood.2020009984","title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Bosutinib; Medicine; Open label; Randomized controlled trial; Internal medicine; Oncology; Imatinib; Nilotinib; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006070934,0.0003203558,0.001597371,0.0001694469,0.00004064462,0.00004284237,0.0002121075,0.0001311426,0.0008554183],"category_scores_gemma":[0.0009251711,0.0002371101,0.0001086339,0.0005865959,0.0001003407,0.0001272454,0.0003623424,0.0002684067,0.00002656968],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002362659,"about_ca_system_score_gemma":0.001501084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003501911,"about_ca_topic_score_gemma":0.0005977339,"domain_scores_codex":[0.9971765,0.0003376385,0.0009255653,0.0006285182,0.0005285814,0.0004032497],"domain_scores_gemma":[0.9982042,0.0003664705,0.0002202443,0.0008453028,0.0001722171,0.000191565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.621223,0.2900729,0.02274021,0.000684923,0.003478668,0.02224615,0.02206869,0.000001401676,0.008388957,0.00001435834,0.0009599354,0.0081208],"study_design_scores_gemma":[0.9719812,0.004161485,0.001829358,0.0005697506,0.001610416,0.0001803802,0.001920927,0.00005198468,0.01696981,0.000009289644,0.0004890031,0.0002264443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936412,0.0009515165,0.000002708528,0.0003723119,0.0001229841,0.004271991,0.00004852101,0.00003794309,0.0005508431],"genre_scores_gemma":[0.9945101,0.00008954946,0.001560471,0.0003124327,0.000103819,0.0009514364,0.00004950981,0.00005461002,0.002368127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3507582,"threshold_uncertainty_score":0.9669071,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0352400247850263,"score_gpt":0.3536891511236019,"score_spread":0.3184491263385756,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}